A large multinational pharmaceutical player is developing a new therapy for sleep disorders including narcolepsy. The overarching goal of the work was to understand the key drivers of value for the new treatment across major global markets, the evidence required to support these value drivers, and any adjustments required to support a targeted, reimbursable product profile. The overall workstream included multiple, related projects including economic modeling, evidence assessment, and early scientific advice.
Economic model and evidence gap assessment
Early HTA advice
Managed HTA Scientific Advice process for NICE (England) and CADTH (Canada):
Insights gained from scientific advice provided external validation of key value drivers and evidence needs.
Based upon the outcomes from the economic model and evidence gap assessments we were able to identify key drivers of value and match these to the existing target product profile and based upon the outcomes of the HTA advice, we were able to identify the key requirements from an HTA perspective to accept the drivers of value. We developed guidance and recommendations for the client to prioritize gaps in evidence and value communication to ensure that their existing target product profile was adjusted to reflect a reimbursable target. Our recommendations were accepted moving into the further development stages.
Jump to a slide with the slide dots.
Refined HCP targeting in rare disease using integrated data, boosting hit rates from 10% to 50% and delivering 3x ROI in 6 months.
Read moreUsed GenAI to benchmark digital voice in oncology, boosting engagement & leadership via LinkedIn, DEI & clinical messaging.
Read moreFuture-proofed data strategy with Putnam: gaps identified, vendors vetted, leading to a first US multi-source tokenized DB.
Read more